title: Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.
abstract: OBJECTIVE
  We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort.
  
  
  METHODS
  From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n=125) or RT and C225 (n=49). Of these, 62 patients had tissue available for HPV analysis.
  
  
  RESULTS
  The median follow-up was 47 months. The 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7% versus 40.2% (P<0.0001), 85.1% versus 35.4% (P<0.0001), and 90.0% versus 56.6% (P<0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3% versus 32.0% (P=0.01), 86.8% versus 43.2% (P=0.002), and 86.7% versus 76.9% (P=0.09), respectively. Multivariate analysis continued to show a benefit for CDDP.
  
  
  CONCLUSIONS
  With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.
authors.affiliation: Departments of *Radiation Oncology †Medical Oncology ‡Pathology §Epidemology and Biostatistics ∥Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: Nadeem
authors.initials: N
authors.lastname: Riaz
authors.forename: Eric
authors.initials: E
authors.lastname: Sherman
authors.forename: Lawrence
authors.initials: L
authors.lastname: Koutcher
authors.forename: Lauren
authors.initials: L
authors.lastname: Shapiro
authors.forename: Nora
authors.initials: N
authors.lastname: Katabi
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Weiji
authors.initials: W
authors.lastname: Shi
authors.forename: Mathew
authors.initials: M
authors.lastname: Fury
authors.forename: Richard
authors.initials: R
authors.lastname: Wong
authors.forename: Suzanne
authors.initials: S
authors.lastname: Wolden
authors.forename: Shyam
authors.initials: S
authors.lastname: Rao
authors.forename: Nancy
authors.initials: N
authors.lastname: Lee
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy* / Q000821:virology; D000068818:Cetuximab / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy* / Q000821:virology; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000628:therapy* / Q000821:virology; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000628:therapy* / Q000821:virology; D008297:Male; D009959:Oropharyngeal Neoplasms / Q000628:therapy* / Q000821:virology; D030361:Papillomavirus Infections / Q000628:therapy*; D016016:Proportional Hazards Models; D050397:Radiotherapy, Intensity-Modulated; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D000970:Antineoplastic Agents; D000068818:Cetuximab; D002945:Cisplatin